TRANSCEND-T2D-1 (NCT06354660), the program's first trial, reported topline results March 19, 2026, with full publication in The Lancet in June
it happens with any significant weight loss
[1] [2] The decision to use these medications concurrently should always be made by your prescribing clinician , who will consider your complete medical history, current medications, and individual risk factors
Ultimately, the integration of fundamental science, technological innovation, and clinical collaboration will establish ferroptosis as a cornerstone of personalized kidney disease management
The Precision Peptide Genetic Test ($99 add-on after the first month) maps 14 metabolic pathways and 49 peptides to reveal your genetic predispositions in GLP1R, GIPR, FTO, and MC4R variants